The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation

British Journal of Pharmacology

Volumn 119, Issue 6, 1996, Pages 1255-1261

  Banner, K H ^a   Moriggi, E ^b   Da Ros, B ^b   Schioppacassi, G ^b   Semeraro, C ^b   Page, C P ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Zambon Group SpA   (Italy)

^c NONE

Author keywords

Eosinophil; Macrophage; Mast cell; Monocyte; Phosphodiesterase

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BENZAFENTIME; CYTOCHROME C; DENBUFYLLINE; HISTAMINE; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; MILRINONE; OVALBUMIN; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SALBUTAMOL; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; GUINEA PIG; HISTAMINE RELEASE; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; MAST CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0029910450     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16030.x     Document Type: Article

References (36)

1. ANDERSON, N. & PEACHELL, P.T. (1994). Effect of isoenzyme selective inhibitors of phosphodiesterase (PDE) on human lung mast cells. FASEB J., 8, A239.
2. AZZAWI, M., BRADLEY, B., JEFFERY, P.K., FREW, A.J., WARDLAW, A.J., KNOWLES, S.G., ASSOUFI, B., COLLINS, J.V., DURHAM, S.R. & KAY, A.B. (1990). Identification of activated T-lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis., 142, 1407-1413.
3. BARNES, P.J., CHUNG, K.F. & PAGE, C.P. (1988). Inflammatory mediators and asthma. Pharmacol. Rev., 40, 49-84.
4. BARNETTE, M., MANNING, C.D., CIELINSKI, L.B., BURMAN, M., CHRISTENSEN, S.B. & TORPHY, T. (1995). The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther., 273, 674-679.
5. BAUER, A.C. & SCHWABE, U. (1980). An improved assay of cyclic 3′, 5′-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn Schmiedeberg's Arch. Pharmacol., 311, 193-198.
6. BOYUM, A. (1968). Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest., 21, 97S, 77-89.
7. BRUIJNZEEL, P.L.B. & VERHAGEN, J. (1989). Lipid metabolism by eosinophils. In Eosinophils in Asthma, ed. Morley, J.M. & Colditz, I. pp. 69-85. San Diego: Academic Press.
8. BRUNELLESCHI, S., PARENTI, A., CENI, E., GIOTTI, A. & FANTOZZI, R. (1992). Enhanced responsiveness of ovalbumin-sensitized guinea pig alveolar macrophages to tachykinins. Br. J. Pharmacol., 107, 964-969.
9. BUTCHERS, P.R., SKIDMORE, I.F., VARDEY, C.J. & WHEELDON, A. (1980). Characterization of the receptor mediating the anti-anaphylactic effects of β-adrenoceptor agonists in human lung tissue in vitro. Br. J. Pharmacol., 71, 633-667.
10. CALHOUN, W.J., STEVENS, C.A. & LAMBERT, S.B. (1991). Modulation of superoxide production of alveolar macrophages and peripheral blood mononuclear cells by β-agonists and theophylline. J. Lab. Clin. Med., 117, 514-522.
11. CHURCH, M.K. & HIROI, J. (1987). Inhibition of IgE dependent histamine release from human dispersed mast cells by antiallergic drugs and salbutamol. Br. J. Pharmacol., 90, 421-429.
12. DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol., 103, 1339-1346.
13. DURHAM, S.R. & KAY, A.B. (1985). Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin. Allergy, 15, 411-418.
14. ELLIOT, K.F.R. & LEONHARD, E.J. (1989). Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP. FEBS Letts., 254, 94-98.
15. FULLER, R.W., O'MALLEY, G., BAKE, A.J. & MACDERMOT, J. (1988). Human alveolar macrophage activation: inhibition by forskolin but not β-adrenoceptor stimulation or phosphodiesterase inhibition. Pulmonary Pharmacol., 1, 101-106.
16. GIEMBYCZ, M.A. & KELLY, J.J. (1994). The current status of phosphodiesterase isozymes. In Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease. ed. Costello, J.F. & Piper, P.S. pp. 27-80. U.K.: Parthenum Press.
17. HARTMAND, A., OCHALSKI, S.J. & CARLSON, R.P. (1993). The effects of anti-inflammatory and anti-allergic drugs on the release of IL-1β and TNF-α in the human blood assay. Agents Actions, 39, Special Conference Issue, C70-72.
18. HATZELMANN, A., TENOR, H. & SCHUDT, C. (1995). Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil function. Br. J. Pharmacol., 114, 821-831.
19. + channel blockers. Eur. J. Pharmacol., 235, 37-43.
20. LAI, C.K.W. & HOLGATE, S.R. (1988). The mast cell in asthma. In Clinical Immunology and Allergy: the Allergic Basis of Asthma. ed. Kay, A.B. pp. 37-65. London: Baliere Tindall.
21. 2-adrenoceptors on human alveolar macrophages. Am. Rev Respir. Dis., 139, 552-555.
22. 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes. Br. J. Pharmacol., 107, 156-160.
23. MIURA, M., BELVISI, M.G., STRETTON, C.D., YACOUB, M.H. & BARNES, P.J. (1992). Role of potassium channels in bronchodilator responses in human airways. Am. Rev. Respir. Dis., 146, 132-136.
24. MOLNAR-KIMBER, K., YONNO, L., HEASLIP, R. & WEICHMAN, B. (1993). Modulation of TNF-α and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions, 39, Special Conference Issue, C77-C79.
25. NIELSON, C.P., VESTAL, R.E., STURM, R.J. & HEASLIP, R. (1990). Effect of selective phosphodiesterase inhibitors in the polymorphonuclear leukocytes respiratory burst. J. Allergy Clin. Immunol., 86, 801-808.
26. PETERS, S.P., SCHULMAN, E.S., SCHLEIMER, R.P., MACGLASHAN JR D.W., NEWBALL, H.H. & LICHTENSTEIN, L.M. (1982). Pharmacological aspects and comparison with human lung tissue fragments. Am. Rev. Respir. Dis., 126, 1034-1039.
27. SCHADE, F.U. & SCHUDT, C. (1993). The specific type III and IV PDE inhibitor, zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol., 230, 9-14.
28. SIMPSON, A.W., REEVES, M.L. & RINK, T.J. (1988). Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem. Pharmacol., 37, 2315-2320.
29. SOUNESS, J.E., CARTER, C.M., DIOCEE, B.K., HASSALL, G.A., WOOD, L.J. & TURNER, N.C. (1991). Characterization of guinea pig eosinophil phosphodiesterase activity. Biochem. Pharmacol., 42, 937-945.
30. SOUNESS, J.E., MASLEN, C., WEBBER, S., FOSTER, M., RAEBURN, D., PALFREYMAN, M.N., ASHTON, M.J. & KARLSSON, J-A. (1995). Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol., 115, 39-46.
31. TENOR, H., HATZELMANN, A., KUPFERSCHMIDT, R., STANCIU, L., DJUKANOVIC, R., SCHUDT, C., WENDEL, A. & CHURCH MK. (1995). Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy, 25, 625-633.
32. TORPHY, T.J. & UNDEM, B.J. (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46, 512-523.
33. TURNER, N.C. & GUERMY, T. (1991). The effect of phosphodiesterase inhibitors on macrophage superoxide generation. Thorax, 46, 107P.
34. VERBURG, K.M. & HENRY, D.P. (1985). Histamine. In Methods of Enzymatic Analysis. ed. Bergmeyer, H.U., Bergmeyer, J. & Graßl, M. Vol. VII. pp. 535-543, 3rd Edition. Weinheim.
35. VERGHESE, M.W., MCCONNELL, R.T., LENHARD, J.M., HAMACHER, L. & JIN, S.L.C. (1995). Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isoenzymes in human monocytic cell lines. Mol. Pharmacol., 47, 1164-1171.
36. 2-adrenergic receptors on eosinophils. Am. Rev. Respir. Dis., 141, 1446-1452.